ReviewCurrent treatment options in oncology2006
Adjuvant and neoadjuvant approaches to treat surgically resectable pancreatic cancer.
Review in Current treatment options in oncology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of selection bias on the utilization of adjuvant therapy for pancreas adenocarcinoma.Annals of surgical oncology · 2010Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adjuvant therapy for pancreatic cancer is currently a controversial topic. Very little is known about the potential components of adjuvant therapy. All published randomized trials evaluating adjuvant therapy for pancreatic cancer have limitations that prevent the establishment of an absolute "standard of care." However, with the recent report of Charite Onkologie Clinical Studies in Gastrointestinal Cancer in abstract form and European Study Group for Pancreatic Cancer-1, it is clear that chemotherapy has an effect as adjuvant therapy. The role of radiation remains unclear. The future of adjuvant therapy is dependent on the investigators designing better trials that answer the important remaining questions: the role of radiation therapy, the integration of newer agents, and the best regimen of those currently available.
Indexed as
Identifiers
16904055What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.